New Biologix develops engineered cell line technology for producing AAV drugs for gene therapy, focusing on making treatments more affordable and accessible.

New Biologix

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

NewBiologix | 2,623 followers on LinkedIn. Developing technologies for the biopharma industry to allow them 
to treat the root causes of diseases and disorders. | Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies.

Chief Digital Officer

Thierry Schuepbach

CFO || Executive Finance Specialist || Facilitator || Startup & Board Advisor || Global || IPMA ||

Tatjana Bauecker, MBA

Senior R&D Director Bioinformatics, NewBiologixSA

Romain Daveau

VP of R&D

Efrain Guzman

NewBiologix

Introducing the Xcell™ Portfolio from NewBiologix—a comprehensive suite of advanced technologies designed to power next-generation gene and cell therapies. Designed with Swiss-precision and flexibility, Xcell™ offers a robust foundation for developing and manufacturing reliable gene therapies. Discover the future of gene therapy innovation. Learn more here >> https://lnkd.in/eDp6ntwn #GeneTherapy #BiotechInnovation #XcellPortfolio

📢 In case you missed it! With gene therapy costs often exceeding $4 million per dose, there's an urgent need for breakthroughs in manufacturing to make these treatments more accessible. In a recent feature with Endpoints News , our CEO, Igor Fisch , discusses how NewBiologix's Xcell™ Portfolio is transforming gene therapy production. By replacing traditional methods with stable cell lines, we aim to streamline rAAV production, improving yield consistency and lowering costs. Read more about our mission: https://lnkd.in/e8X2y_YM #NewBiologix #GeneTherapy #Innovation

The #NewBiologix team is having a wonderful time at BIO-Europe! As we continue to push boundaries in gene therapy and biotech, we’re excited to share insights, explore partnerships and engage in meaningful discussions with industry peers. If you’re attending, let’s connect and discuss how partnering with us can help advance gene therapies to improve scalability, lower production costs and accelerate affordable patient access. We look forward to the rest of the week! #BIOEurope #Innovation #GeneTherapy

The high cost of #GeneTherapies , which can reach more than $4 million per dose, highlights the need for manufacturing solutions that can deliver these life-saving treatments to patients more affordably and at scale. At NewBiologix, we're leading the way with our Xcell™ Portfolio, a suite of technologies to streamline rAAV production, improve yield consistency and lower costs. Our CEO, Igor Fisch , Ph.D., discusses these challenges and our innovative solutions in a recent article featured in Endpoints News . By developing stable cell lines to replace transient transfection methods, we’re tackling cost, scalability, and regulatory hurdles, making gene therapies more accessible. Read more: https://lnkd.in/edjeqEK4 . #NewBiologix

#NewBiologix is proud to launch the Xcell™ Portfolio, a suite of advanced services and engineered cell lines that address the biggest challenges in viral vector manufacturing—low yields, batch inconsistencies, scalability issues, and high costs. Xcell includes: - Xcell™ Eng-HEK293 Cell Line: High-performance HEK293 line optimized for transient rAAV production. - Xcell™ rAAV Production & Testing Platform: Streamlined solution for efficient rAAV candidate production and testing. - Xcell™ Genomic Analytical Platform: Custom sequencing and bioinformatics solutions for comprehensive rAAV analysis. With our proprietary HEK293-based technology and decades of expertise, we enable our partners in research, #biotech , and pharma to develop safer and more effective gene therapies at scale. Read the full press release for more details: https://lnkd.in/eiKuvxWj

#NewBiologix CEO & Co-Founder Igor Fisch and Chief Operating Officer Déborah Ley are headed to Biotechnology Innovation Organization -Europe in Stockholm, Sweden, from November 4–6, 2024! NewBiologix is committed to helping partners advance the treatment of rare, chronic, and incurable diseases by closing the innovation gap in economically viable, large-scale viral vector production for gene therapy. Let's connect and explore how we can drive this mission forward together—reach out to request a meeting! #BIOEurope #Innovation #GeneTherapy

According to data presented at the 2024 Cell & Gene Meeting on the Mesa, the cell and gene therapy industry is beginning to recover from recent investment challenges, with $10.9 billion raised in the first half of this year. While smaller, preclinical-stage companies have faced difficulties securing funding, there is renewed optimism for the future. With increasing investments in cell and gene therapy, we are excited about the opportunity to help our partners develop life-changing innovations and offer hope for improved quality of life to patients. Read more 👉 https://bit.ly/3UtH2Ur

#NewBiologix is on the ground at the European Society of Gene and Cell Therapy Annual Meeting in Rome! We've had a productive week engaging in lively discussions, cutting-edge research presentations, and collaborative exchanges with top scientific leaders in #GeneTherapy . Please reach out to Efrain Guzman , Luca Nanni , or Pelin Kolçak Yaşlı, Ph.D. , to continue discussions about how NewBiologix can help you revolutionize the field of gene therapy! #ESGCT2024

We are excited to announce that two of our abstracts have been selected for poster presentations at the 31st Annual European Society of Gene and Cell Therapy Congress (ESGCT)! Our presentations will highlight our innovative #CellLine technologies designed to overcome the traditional limitations of #GeneTherapy production. Presentation Details: Generation and Characterization of a HEK293 Cell Line for rAAV production October 22 | 19:30 - 21:00 CEST | P0039 An Integrated Platform for the Analysis and Quality Control of rAAV Vectors Based on Long-read Sequencing October 23 | 13:30 - 15:00 CEST | P0174 Join us in Rome to explore how we’re advancing the future of gene therapy! #NewBiologix #ESGCT2024

Press Release: NewBiologix has been selected for two poster presentations at the 31st Annual European Society for Gene & Cell Therapy Congress (ESGCT), taking place October 22-25, 2024, at La Nuvola in Rome, Italy. Pelin Kolçak Yaşlı, Ph.D. to present Oct. 22 at 19:30 and Luca Nanni on Oct. 23 at 13:30. Learn More about the presentations here >> https://bit.ly/3UddSsx

Metric
Company Name	New Biologix	Campus Biotech
Symbol
MSH ID	COM:NEWBIOLOGIX	CH:CAMPUSBIOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences
Country	US	CH
Stage
Employee Count
Website	newbiologix.com	campusbiotech.ch
LinkedIn	newbiologix	campus-biotech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.59
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NEWB

COM:NEWBIOLOGIX

New Biologix

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue